Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geert R D'Haens

Showing results (1-10 of 202) with videos related to

Pageof 21
Sort By:
Nature Reviews. Gastroenterology & Hepatology|February 6, 2010
Top-down therapy for IBD: rationale and requisite evidenceGeert R D'Haens
European Journal of Gastroenterology & Hepatology|March 1, 2003
Infliximab as disease-modifying therapyGeert R D'Haens
Gastroenterology|June 21, 2019
Fecal Microbial Transplantation for Diseases Beyond Recurrent Clostridium Difficile InfectionGeert R D'Haens, Christian Jobin
Expert Opinion on Biological Therapy|January 31, 2019
Rational and clinical development of the anti-MAdCAM monoclonal antibody for the treatment of IBDMarjolijn Duijvestein, Geert R D'Haens
Expert Opinion on Biological Therapy|November 26, 2019
Anti-interleukin-23 agents for the treatment of ulcerative colitisJurij Hanžel, Geert R D'Haens
Expert Review of Clinical Pharmacology|May 8, 2014
Vedolizumab for the treatment of ulcerative colitisSvend T Rietdijk, Geert R D'Haens
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 2, 2025
ReplySuzanne I Anjie, Geert R D'Haens
Journal of Digestive Diseases|February 20, 2013
Recent developments in the treatment of inflammatory bowel diseaseSvend T Rietdijk, Geert R D'Haens
Gut|January 12, 2021
25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the futureGeert R D'Haens, Sander van Deventer
Lancet (London, England)|April 2, 2019
Infliximab biosimilar CT-P13 in Crohn's diseaseKrisztina B Gecse, Geert R D'Haens
Pageof 21

Showing results (1-10 of 202) with videos related to

Sort By:
Pageof 21
Nature Reviews. Gastroenterology & Hepatology|February 6, 2010
Top-down therapy for IBD: rationale and requisite evidenceGeert R D'Haens
European Journal of Gastroenterology & Hepatology|March 1, 2003
Infliximab as disease-modifying therapyGeert R D'Haens
Gastroenterology|June 21, 2019
Fecal Microbial Transplantation for Diseases Beyond Recurrent Clostridium Difficile InfectionGeert R D'Haens, Christian Jobin
Expert Opinion on Biological Therapy|January 31, 2019
Rational and clinical development of the anti-MAdCAM monoclonal antibody for the treatment of IBDMarjolijn Duijvestein, Geert R D'Haens
Expert Opinion on Biological Therapy|November 26, 2019
Anti-interleukin-23 agents for the treatment of ulcerative colitisJurij Hanžel, Geert R D'Haens
Expert Review of Clinical Pharmacology|May 8, 2014
Vedolizumab for the treatment of ulcerative colitisSvend T Rietdijk, Geert R D'Haens
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 2, 2025
ReplySuzanne I Anjie, Geert R D'Haens
Journal of Digestive Diseases|February 20, 2013
Recent developments in the treatment of inflammatory bowel diseaseSvend T Rietdijk, Geert R D'Haens
Gut|January 12, 2021
25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the futureGeert R D'Haens, Sander van Deventer
Lancet (London, England)|April 2, 2019
Infliximab biosimilar CT-P13 in Crohn's diseaseKrisztina B Gecse, Geert R D'Haens
Pageof 21